Jubilant Ingrevia Q2 FY27: revenue up 24% to record Rs 1,394 crore, EBITDA up 51%; 40% stake in ZettaOne marks EDMS entry
Q2 FY27 revenue up 24% YoY to a record Rs 1,394 crore, EBITDA up 51% to Rs 221 crore, PAT up 61% to Rs 111 crore.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue
- Rs 1,394 crore, up 24% YoY
- Q2 FY27 EBITDA
- Rs 221 crore, up 51%, 16% margin
- Q2 FY27 PAT
- Rs 111 crore, up 61%
- Period
- Q2 FY27 (quarter ended September 30, 2026)
- Positioning
- Jubilant Ingrevia presents itself as a three-segment chemicals company spanning Specialty Chemicals (incl. CDMO), Nutrition & Health Solutions and Chemical Intermediates, now building an integrated Electronics & Semiconductor platform.
📈 Q2 FY27 total revenue rose 24% YoY to Rs 1,394 crore and EBITDA rose 51% to Rs 221 crore with a 16% margin; PAT was Rs 111 crore, up 61%. For H1 FY27 revenue was Rs 2,695 crore (up 25%) and EBITDA Rs 431 crore (up 44%).
📈 By segment, Specialty Chemicals revenue was Rs 560 crore with a 25% EBITDA margin, Nutrition & Health Solutions revenue rose 50% to Rs 270 crore, and Chemical Intermediates EBITDA jumped 226% to Rs 64 crore on improved realizations. The company notes agrochemicals pricing remains under pressure from China overcapacity and B3 feed pricing softened in recent weeks.
🏭 Management states it expects growth across all three business segments in FY27, particularly in Acetyls where it hopes for higher volumes helped by European plant closures, and says the new Multi-Purpose Plant remains on track for commissioning by year-end.
📈 The company says it acquired a 40% stake in ZettaOne Technologies for Rs 189.2 crore in cash to enter the EDMS space; the presentation states ZettaOne revenue grew from 51 to 99 (INR Cr) over FY24-FY26 and expects 60-70% growth in FY27 with mid-teen EBITDA.
Also from Jubilant Ingrevia
Jubilant Ingrevia uploads audio recording of Q2/H1 FY27 investors' conference call held October 27, 2026
27 Oct 2026
Jubilant Ingrevia Q2 FY27: Nutrition EBITDA up 87% YoY, Chemical Intermediates revenue up 24%; ZettaOne to build Bengaluru plant
27 Oct 2026
Jubilant Ingrevia reported revenue growth of 24%, with its chemical segment up 27% and nutrition and health segment up 51%, and net profit surging 61%
27 Oct 2026
More numbers
- Total revenue, Q2 FY271,394 (Rs Crore)
- Total EBITDA, Q2 FY27221 (Rs Crore)
- PAT after exceptional items, Q2 FY27111 (Rs Crore)
- EBITDA margin, Q2 FY2716%
- Total revenue, H1 FY272,695 (Rs Crore)
- Total EBITDA, H1 FY27431 (Rs Crore)
- Specialty Chemicals revenue, Q2 FY27560 (Rs Crore)
- Nutrition & Health Solutions revenue, Q2 FY27270 (Rs Crore)
- Chemical Intermediates EBITDA, Q2 FY2764 (Rs Crore)
- ZettaOne 40% stake consideration₹189.2 Cr
- ZettaOne revenue, FY2699 (INR Cr)
- Basic EPS, Q2 FY277.1
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.